GSA Capital Partners LLP Buys Shares of 82,830 Xeris Biopharma Holdings, Inc. $XERS

GSA Capital Partners LLP bought a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 2nd quarter, Holdings Channel reports. The firm bought 82,830 shares of the company’s stock, valued at approximately $656,000.

Other hedge funds have also recently made changes to their positions in the company. Cetera Investment Advisers grew its stake in shares of Xeris Biopharma by 3.9% in the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after buying an additional 1,735 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after acquiring an additional 1,820 shares in the last quarter. Royal Bank of Canada boosted its holdings in Xeris Biopharma by 6.5% in the fourth quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock worth $304,000 after acquiring an additional 2,351 shares in the last quarter. AlphaCentric Advisors LLC grew its stake in shares of Xeris Biopharma by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock worth $266,000 after acquiring an additional 2,494 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new position in shares of Xeris Biopharma during the fourth quarter valued at $25,000. 42.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Barclays raised their price target on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Xeris Biopharma has a consensus rating of “Hold” and a consensus target price of $12.00.

Insider Activity at Xeris Biopharma

In related news, Director Dawn Halkuff sold 20,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $121,800.00. Following the completion of the sale, the director directly owned 95,000 shares of the company’s stock, valued at approximately $578,550. This represents a 17.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the sale, the director directly owned 126,500 shares of the company’s stock, valued at $770,385. This represents a 11.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 271,499 shares of company stock worth $2,038,917 in the last quarter. 4.35% of the stock is currently owned by insiders.

Xeris Biopharma Price Performance

NASDAQ XERS opened at $8.60 on Friday. The business’s fifty day moving average is $8.08 and its 200 day moving average is $6.86. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The company has a market capitalization of $1.57 billion, a PE ratio of -78.18 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The company had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.